

# Henk-Jan Guchelaar

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5786549/henk-jan-guchelaar-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

|                    |                          |                |                 |
|--------------------|--------------------------|----------------|-----------------|
| 356<br>papers      | 13,545<br>citations      | 55<br>h-index  | 104<br>g-index  |
| 373<br>ext. papers | 16,241<br>ext. citations | 4.8<br>avg, IF | 6.38<br>L-index |

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 356 | Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , <b>2014</b> , 506, 376-81  | 50.4 | 1426      |
| 355 | Pharmacogenetics: from bench to byte--an update of guidelines. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 89, 662-73  | 6.1  | 684       |
| 354 | Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2000</b> , 46, 171-9  | 5.1  | 490       |
| 353 | The risk of cancer in users of statins. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2388-94  | 2.2  | 431       |
| 352 | Clinical pharmacokinetics of tyrosine kinase inhibitors. <i>Cancer Treatment Reviews</i> , <b>2009</b> , 35, 692-706   | 14.4 | 316       |
| 351 | Cardiotoxicity of cytotoxic drugs. <i>Cancer Treatment Reviews</i> , <b>2004</b> , 30, 181-91  | 14.4 | 264       |
| 350 | Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. <i>Cancer Treatment Reviews</i> , <b>2004</b> , 30, 609-41   | 14.4 | 235       |
| 349 | Liposomal drug formulations in cancer therapy: 15 years along the road. <i>Drug Discovery Today</i> , <b>2012</b> , 17, 160-6  | 8.8  | 196       |
| 348 | A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 1765-75   |      | 193       |
| 347 | Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. <i>Clinical and Translational Science</i> , <b>2020</b> , 13, 116-124 | 4.9  | 177       |
| 346 | Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 1087-95                                |      | 164       |
| 345 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 770-777  | 6.1  | 161       |
| 344 | Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4406-12  | 2.2  | 161       |
| 343 | Pharmacogenetics: from bench to byte. <i>Clinical Pharmacology and Therapeutics</i> , <b>2008</b> , 83, 781-7  | 6.1  | 158       |
| 342 | Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 101, 341-358  | 6.1  | 157       |
| 341 | Making sense of big data in health research: Towards an EU action plan. <i>Genome Medicine</i> , <b>2016</b> , 8, 71   | 14.4 | 146       |
| 340 | DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. <i>Lancet Oncology</i> , <b>2018</b> , 19, 1459-1467   | 21.7 | 139       |

|     |  |      |     |
|-----|--|------|-----|
| 339 | Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3455-68   | 12.9 | 138 |
| 338 | Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 620-9  | 12.9 | 130 |
| 337 | Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003394  | 6    | 127 |
| 336 | Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2423-9  | 2.2  | 126 |
| 335 | Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. <i>Supportive Care in Cancer</i> , <b>1997</b> , 5, 281-8   | 3.9  | 123 |
| 334 | Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. <i>Gastroenterology</i> , <b>2015</b> , 149, 907-17.e7   | 13.3 | 121 |
| 333 | Translating pharmacogenomics: challenges on the road to the clinic. <i>PLoS Medicine</i> , <b>2007</b> , 4, e209   | 11.6 | 120 |
| 332 | Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 599-618   | 6.1  | 113 |
| 331 | Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1087-94  | 4.3  | 110 |
| 330 | Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. <i>Anti-Cancer Drugs</i> , <b>2014</b> , 25, 140-9  | 2.4  | 109 |
| 329 | Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2830-9  |      | 107 |
| 328 | Quantitative determination of the macrolide antibiotics erythromycin, roxithromycin, azithromycin and clarithromycin in human serum by high-performance liquid chromatography using pre-column derivatization with 9-fluorenylmethyloxycarbonyl chloride and fluorescence detection. <i>Biomedical Applications</i> , <b>1999</b> , 720, 88-97 |      | 104 |
| 327 | Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 187-97  | 3.2  | 103 |
| 326 | Effect of milk thistle ( <i>Silybum marianum</i> ) on the pharmacokinetics of irinotecan. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 7800-6   | 12.9 | 102 |
| 325 | Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 935-50   | 14.4 | 88  |
| 324 | Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 7394-400  | 12.9 | 88  |
| 323 | Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 46-51  |      | 86  |
| 322 | Sirolimus and everolimus in kidney transplantation. <i>Drug Discovery Today</i> , <b>2015</b> , 20, 1243-9   | 8.8  | 83  |

|     |   |      |    |
|-----|---|------|----|
| 321 | Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. <i>European Journal of Cancer</i> , <b>2016</b> , 54, 40-48   | 7.5  | 82 |
| 320 | Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1375-81   | 2.4  | 79 |
| 319 | Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5668-73  | 12.9 | 77 |
| 318 | Mitotane has a strong and a durable inducing effect on CYP3A4 activity. <i>European Journal of Endocrinology</i> , <b>2011</b> , 164, 621-6   | 6.5  | 76 |
| 317 | Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. <i>Oncologist</i> , <b>2011</b> , 16, 1239-49  | 5.7  | 75 |
| 316 | Apoptosis: molecular mechanisms and implications for cancer chemotherapy. <i>International Journal of Clinical Pharmacy</i> , <b>1997</b> , 19, 119-25  |      | 71 |
| 315 | Clinical and pharmacogenetic factors associated with irinotecan toxicity. <i>Cancer Treatment Reviews</i> , <b>2008</b> , 34, 656-69  | 14.4 | 68 |
| 314 | Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 504-10  | 3.2  | 68 |
| 313 | Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 1829-34  | 7.5  | 67 |
| 312 | Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 15-21  | 12.9 | 67 |
| 311 | Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. <i>Clinical Therapeutics</i> , <b>2013</b> , 35, 1946-54   | 3.5  | 63 |
| 310 | A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?. <i>European Heart Journal</i> , <b>2012</b> , 33, 165-75  | 9.5  | 60 |
| 309 | Individualized dosing of tyrosine kinase inhibitors: are we there yet?. <i>Drug Discovery Today</i> , <b>2015</b> , 20, 18-36   | 8.8  | 59 |
| 308 | A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2013</b> , 937, 33-43 | 3.2  | 59 |
| 307 | Flucytosine: correlation between toxicity and pharmacokinetic parameters. <i>Chemotherapy</i> , <b>2000</b> , 46, 86-94   | 3.2  | 59 |
| 306 | Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. <i>Pharmacogenomics</i> , <b>2011</b> , 12, 159-70  | 2.6  | 58 |
| 305 | Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1998</b> , 42, 77-83   | 3.5  | 58 |
| 304 | Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 163-75  | 2.6  | 57 |

|     |   |      |    |
|-----|---|------|----|
| 303 | Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. <i>Haematologica</i> , <b>2010</b> , 95, 1943-51  | 6.6  | 56 |
| 302 | CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. <i>European Urology</i> , <b>2015</b> , 68, 621-9  | 10.2 | 55 |
| 301 | Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2014</b> , 3, e100   | 4.5  | 55 |
| 300 | Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. <i>Clinical Oncology</i> , <b>1994</b> , 6, 40-8   | 2.8  | 55 |
| 299 | Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. <i>Pharmacogenomics</i> , <b>2007</b> , 8, 141-50  | 2.6  | 54 |
| 298 | Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 1277-86   | 2.6  | 53 |
| 297 | Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 636-646   | 2.2  | 52 |
| 296 | Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. <i>Annals of Oncology</i> , <b>2009</b> , 20, 358-64   | 10.3 | 52 |
| 295 | Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. <i>Drug Discovery Today</i> , <b>2007</b> , 12, 125-31  | 8.8  | 52 |
| 294 | Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. <i>European Journal of Human Genetics</i> , <b>2020</b> , 28, 508-517  | 5.3  | 51 |
| 293 | Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. <i>Clinical Pharmacokinetics</i> , <b>2012</b> , 51, 467-80  | 6.2  | 49 |
| 292 | Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 572-8   | 7.5  | 48 |
| 291 | The role of pharmacogenetics in capecitabine efficacy and toxicity. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 50, 9-22  | 14.4 | 47 |
| 290 | Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. <i>Drug Discovery Today</i> , <b>2014</b> , 19, 1572-86   | 8.8  | 47 |
| 289 | A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2000</b> , 44, 2286-90  | 5.9  | 47 |
| 288 | The role of pharmacogenetics in the treatment of osteosarcoma. <i>Drug Discovery Today</i> , <b>2016</b> , 21, 1775-1786  | 8.6  | 47 |
| 287 | Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx). <i>European Journal of Clinical Pharmacology</i> , <b>2017</b> , 73, 1247-1252 | 2.8  | 45 |
| 286 | Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 935-44   | 1.9  | 45 |

|     |   |      |    |
|-----|---|------|----|
| 285 | Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 2828-34                   | 5.6  | 45 |
| 284 | Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2312-2318  | 12.9 | 44 |
| 283 | Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 866-873  | 6.1  | 43 |
| 282 | Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 698-707  | 5.6  | 43 |
| 281 | Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 331-8   | 3.2  | 41 |
| 280 | Lapatinib for advanced or metastatic breast cancer. <i>Oncologist</i> , <b>2012</b> , 17, 536-42  | 5.7  | 41 |
| 279 | Pharmacogenetics of EGFR and VEGF inhibition. <i>Drug Discovery Today</i> , <b>2007</b> , 12, 1054-60   | 8.8  | 40 |
| 278 | CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. <i>European Journal of Pharmaceutical Sciences</i> , <b>2003</b> , 20, 451-7   | 5.1  | 40 |
| 277 | Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. <i>PLoS ONE</i> , <b>2014</b> , 9, e115869 | 3.7  | 40 |
| 276 | Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing. <i>Human Mutation</i> , <b>2017</b> , 38, 310-316   | 4.7  | 39 |
| 275 | Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. <i>International Journal of Clinical Pharmacy</i> , <b>2011</b> , 33, 33-43  | 2.3  | 39 |
| 274 | Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 2889-2902            | 3.8  | 39 |
| 273 | Pharmacogenetic Information in Clinical Guidelines: The European Perspective. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 795-801  | 6.1  | 38 |
| 272 | Low literacy and written drug information: information-seeking, leaflet evaluation and preferences, and roles for images. <i>International Journal of Clinical Pharmacy</i> , <b>2016</b> , 38, 1372-1379   | 2.3  | 38 |
| 271 | Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2018</b> , 25, 893-898                      | 8.6  | 37 |
| 270 | Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. <i>Journal of Investigative Dermatology</i> , <b>2009</b> , 129, 2620-7   | 4.3  | 37 |
| 269 | Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. <i>Expert Review of Clinical Pharmacology</i> , <b>2019</b> , 12, 523-536  | 3.8  | 36 |
| 268 | A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2019</b> , 8, 720-737  | 4.5  | 36 |



|     |  |      |    |
|-----|--|------|----|
| 267 | Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 175-184   | 1.5  | 36 |
| 266 | Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. <i>Journal of Immunotherapy</i> , <b>2011</b> , 34, 307-19               | 5    | 36 |
| 265 | Marginal increase of sunitinib exposure by grapefruit juice. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 695-703   | 3.5  | 36 |
| 264 | Preventing adverse drug events in hospital practice: an overview. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2007</b> , 16, 1129-35  | 2.6  | 36 |
| 263 | Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin?. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 2580-9  | 7.5  | 36 |
| 262 | Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,   | 5.1  | 36 |
| 261 | Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. <i>European Journal of Clinical Pharmacology</i> , <b>2016</b> , 72, 163-74   | 2.8  | 35 |
| 260 | Acute effects of high-dose furosemide on residual renal function in CAPD patients. <i>Peritoneal Dialysis International</i> , <b>2003</b> , 23, 339-47   | 2.8  | 35 |
| 259 | Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia. <i>Japanese Journal of Clinical Oncology</i> , <b>2011</b> , 41, 519-29  | 2.8  | 33 |
| 258 | Medication errors: hospital pharmacist perspective. <i>Drugs</i> , <b>2005</b> , 65, 1735-46   | 12.1 | 33 |
| 257 | Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands. <i>BMC Medicine</i> , <b>2019</b> , 17, 110  | 11.4 | 32 |
| 256 | Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 243-7   | 1.9  | 32 |
| 255 | Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial. <i>International Journal of Endocrinology</i> , <b>2015</b> , 2015, 348124                      | 2.7  | 32 |
| 254 | Acute Effects of High-Dose Furosemide on Residual Renal Function in CAPD Patients. <i>Peritoneal Dialysis International</i> , <b>2003</b> , 23, 339-347  | 2.8  | 32 |
| 253 | Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact. <i>Genes</i> , <b>2019</b> , 10,   | 4.2  | 30 |
| 252 | Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1147-1153   | 10.3 | 30 |
| 251 | Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection. <i>Biomedical Applications</i> , <b>1999</b> , 734, 203-10 |      | 30 |
| 250 | A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. <i>European Journal of Cancer</i> , <b>2019</b> , 107, 60-67  | 7.5  | 30 |

|     |   |      |    |
|-----|---|------|----|
| 249 | A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3436-41                         | 12.9 | 29 |
| 248 | Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 465-72  | 3.2  | 29 |
| 247 | Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. <i>Journal of Molecular Diagnostics</i> , <b>2010</b> , 12, 746-9  | 5.1  | 29 |
| 246 | Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism. <i>European Journal of Clinical Pharmacology</i> , <b>2017</b> , 73, 1589-1598   | 2.8  | 28 |
| 245 | Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 363-70   | 2.8  | 28 |
| 244 | Application of the Bow-Tie model in medication safety risk analysis: consecutive experience in two hospitals in the Netherlands. <i>Drug Safety</i> , <b>2009</b> , 32, 663-73  | 5.1  | 28 |
| 243 | Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 1335-1342                 | 8.7  | 27 |
| 242 | Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 144, 599-606 | 4.4  | 27 |
| 241 | Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. <i>Pharmacogenomics</i> , <b>2012</b> , 13, 1087-94                                    | 2.6  | 27 |
| 240 | Explaining variability in ciclosporin exposure in adult kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 579-90   | 2.8  | 27 |
| 239 | Therapeutic modulation of k-ras signaling in colorectal cancer. <i>Drug Discovery Today</i> , <b>2010</b> , 15, 502-16  | 8.8  | 27 |
| 238 | Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. <i>British Journal of Clinical Pharmacology</i> , <b>2005</b> , 59, 310-3  | 3.8  | 27 |
| 237 | Quantitative determination of melatonin in human plasma and cerebrospinal fluid with high-performance liquid chromatography and fluorescence detection. <i>Biomedical Chromatography</i> , <b>2000</b> , 14, 306-10                 | 1.7  | 27 |
| 236 | A nationwide survey of pharmacists' perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 215-225     | 2.6  | 26 |
| 235 | Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 413-9            | 3.2  | 26 |
| 234 | Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 2183-7                                     | 2.4  | 25 |
| 233 | Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS. <i>Journal of the Neurological Sciences</i> , <b>2001</b> , 191, 121-5  | 3.2  | 25 |
| 232 | Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping. <i>Biomedical Chromatography</i> , <b>1999</b> , 13, 309-14       | 1.7  | 25 |



|     |  |     |    |
|-----|--|-----|----|
| 231 | Clinical development of gene- and cell-based therapies: overview of the European landscape. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2016</b> , 3, 16073   | 6.4 | 25 |
| 230 | High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 772-780                 | 4.5 | 24 |
| 229 | Integration of sequence data from a Consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk gene. <i>PLoS ONE</i> , <b>2014</b> , 9, e87645                | 3.7 | 24 |
| 228 | Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. <i>Cytotherapy</i> , <b>2010</b> , 12, 933-44          | 4.8 | 24 |
| 227 | Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study. <i>PLoS ONE</i> , <b>2014</b> , 9, e112201         | 3.7 | 24 |
| 226 | Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 2005-12   | 2.6 | 23 |
| 225 | Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 2882-8                             | 3.2 | 23 |
| 224 | A computerized adverse drug event alerting system using clinical rules: a retrospective and prospective comparison with conventional medication surveillance in the Netherlands. <i>Drug Safety</i> , <b>2011</b> , 34, 233-42 | 5.1 | 23 |
| 223 | Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease. <i>European Journal of Clinical Pharmacology</i> , <b>2009</b> , 65, 1245-51                       | 2.8 | 23 |
| 222 | Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 676-87   | 3.2 | 23 |
| 221 | Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation. <i>Cytotherapy</i> , <b>2016</b> , 18, 797-805  | 4.8 | 23 |
| 220 | The extent and effects of patient involvement in pictogram design for written drug information: a short systematic review. <i>Drug Discovery Today</i> , <b>2018</b> , 23, 1312-1318   | 8.8 | 23 |
| 219 | Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis. <i>Acta Oncologica</i> , <b>2017</b> , 56, 582-589                           | 3.2 | 22 |
| 218 | Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 391-402   | 6.1 | 22 |
| 217 | Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice. <i>Current Pharmaceutical Biotechnology</i> , <b>2017</b> , 18, 204-209      | 2.6 | 22 |
| 216 | Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 78, 63-71  | 3.5 | 22 |
| 215 | The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 833-54  | 6.2 | 22 |
| 214 | Dried blood spot analysis for therapeutic drug monitoring of pazopanib. <i>Journal of Clinical Pharmacology</i> , <b>2015</b> , 55, 1344-50  | 2.9 | 22 |

|     |  |      |    |
|-----|--|------|----|
| 213 | Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 1683-90   | 2.6  | 22 |
| 212 | Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes. <i>Anti-Cancer Drugs</i> , <b>2006</b> , 17, 1099-105   | 2.4  | 22 |
| 211 | A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care. <i>European Journal of Human Genetics</i> , <b>2019</b> , 27, 1532-1541   | 5.3  | 21 |
| 210 | Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , <b>2015</b> , 33, 1242-7   | 4.3  | 21 |
| 209 | Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). <i>Breast Cancer Research</i> , <b>2016</b> , 18, 3          | 8.3  | 21 |
| 208 | Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 1517-23   | 2.6  | 21 |
| 207 | Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , <b>2011</b> , 41, 1168-76 | 2.8  | 21 |
| 206 | Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 459-65  | 7.5  | 21 |
| 205 | Use of angiotensin receptor antagonists in patients with ACE inhibitor induced angioedema. <i>International Journal of Clinical Pharmacy</i> , <b>2004</b> , 26, 191-2   |      | 21 |
| 204 | Implementation of a computerized physician medication order entry system at the Academic Medical Centre in Amsterdam. <i>International Journal of Clinical Pharmacy</i> , <b>2003</b> , 25, 88-93  |      | 21 |
| 203 | Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 953-963  | 6.1  | 20 |
| 202 | Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. <i>Nature Genetics</i> , <b>2013</b> , 45, 468-9   | 36.3 | 20 |
| 201 | The antioxidant N-acetylcysteine does not delay disease onset and death in a transgenic mouse model of amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , <b>1998</b> , 44, 293   | 9.4  | 20 |
| 200 | Cyclopentenyl cytosine (CPEC): an overview of its in vitro and in vivo activity. <i>Current Cancer Drug Targets</i> , <b>2007</b> , 7, 504-9   | 2.8  | 20 |
| 199 | Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 8308-13  | 12.9 | 19 |
| 198 | Minimum Effective Doses of Succinylcholine and Rocuronium During Electroconvulsive Therapy: A Prospective, Randomized, Crossover Trial. <i>Anesthesia and Analgesia</i> , <b>2016</b> , 123, 587-96  | 3.9  | 19 |
| 197 | Development of cell therapy medicinal products by academic institutes. <i>Drug Discovery Today</i> , <b>2016</b> , 21, 1206-12   | 8.8  | 19 |
| 196 | FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 373-81  | 2.6  | 18 |

|     |  |     |    |
|-----|--|-----|----|
| 195 | Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 58-65   | 3.2 | 18 |
| 194 | Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 1477-84                                | 2.8 | 18 |
| 193 | Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 73, 87-96  | 3.5 | 18 |
| 192 | Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Cancer Epidemiology</i> , <b>2009</b> , 33, 391-5  | 2.8 | 18 |
| 191 | Pharmacogenetics of antiparkinsonian drug treatment: a systematic review. <i>Pharmacogenomics</i> , <b>2007</b> , 8, 159-76  | 2.6 | 18 |
| 190 | Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 553-61   | 3.8 | 18 |
| 189 | EU decision-making for marketing authorization of advanced therapy medicinal products: a case study. <i>Drug Discovery Today</i> , <b>2018</b> , 23, 1328-1333   | 8.8 | 17 |
| 188 | Implementation of Pharmacogenomics in Everyday Clinical Settings. <i>Advances in Pharmacology</i> , <b>2018</b> , 83, 219-246  | 5.7 | 17 |
| 187 | Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 63-73   | 2.6 | 17 |
| 186 | Impact of chemotherapy-induced nausea and vomiting on quality of life in Indonesian patients with gynecologic cancer. <i>International Journal of Gynecological Cancer</i> , <b>2012</b> , 22, 139-45  | 3.5 | 17 |
| 185 | Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time. <i>European Journal of Cancer</i> , <b>2020</b> , 141, 9-20  | 7.5 | 17 |
| 184 | Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 721-9  | 2.6 | 17 |
| 183 | Evaluation of rule effectiveness and positive predictive value of clinical rules in a Dutch clinical decision support system in daily hospital pharmacy practice. <i>Artificial Intelligence in Medicine</i> , <b>2013</b> , 59, 15-21                       | 7.4 | 16 |
| 182 | Exposure to phototoxic NSAIDs and quinolones is associated with an increased risk of melanoma. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 1437-44  | 2.8 | 16 |
| 181 | A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis. <i>Biomedical Chromatography</i> , <b>2004</b> , 18, 723-6   | 1.7 | 16 |
| 180 | Simultaneous determination of clozapine, norclozapine and clozapine-N-oxide in human plasma by high-performance liquid chromatography with ultraviolet detection. <i>Biomedical Chromatography</i> , <b>2001</b> , 15, 280-6                                 | 1.7 | 16 |
| 179 | More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1873-1881  | 4.5 | 15 |
| 178 | Patients' preferences for visuals: differences in the preferred level of detail, type of background and type of frame of icons depicting organs between literate and low-literate people. <i>Patient Education and Counseling</i> , <b>2015</b> , 98, 226-33 | 3.1 | 15 |

|     |   |     |    |
|-----|---|-----|----|
| 177 | A brighter future for the implementation of pharmacogenomic testing. <i>European Journal of Human Genetics</i> , <b>2016</b> , 24, 1658-1660  | 5.3 | 15 |
| 176 | Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. <i>Pharmacogenomics Journal</i> , <b>2017</b> , 17, 42-46  | 3.5 | 14 |
| 175 | Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 675-83                                | 1.9 | 14 |
| 174 | Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 137-43   | 4.3 | 14 |
| 173 | Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 953-62  | 4.3 | 14 |
| 172 | Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 1197-210  | 4   | 14 |
| 171 | A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making. <i>Cytotherapy</i> , <b>2018</b> , 20, 769-778                         | 4.8 | 13 |
| 170 | Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression. <i>Scientific Reports</i> , <b>2018</b> , 8, 5250  | 4.9 | 13 |
| 169 | Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 2761-2769 <sup>38</sup> |     | 13 |
| 168 | The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 1125-1132   | 2.6 | 13 |
| 167 | Non-homologous end-joining pathway associated with occurrence of myocardial infarction: gene set analysis of genome-wide association study data. <i>PLoS ONE</i> , <b>2013</b> , 8, e56262  | 3.7 | 13 |
| 166 | The potential role of computerisation and information technology in improving prescribing in hospitals. <i>International Journal of Clinical Pharmacy</i> , <b>2003</b> , 25, 83-7  |     | 13 |
| 165 | Simultaneous determination of flucytosine and fluorouracil in human plasma by high-performance liquid chromatography. <i>Biomedical Chromatography</i> , <b>2001</b> , 15, 89-94  | 1.7 | 13 |
| 164 | Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 838-845  | 1.5 | 12 |
| 163 | Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for and CD39. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1055-1061  | 2.4 | 12 |
| 162 | A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review. <i>Expert Review of Molecular Diagnostics</i> , <b>2016</b> , 16, 605-18                                  | 3.8 | 12 |
| 161 | Genetic polymorphisms of 3' untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 172, 401-411  | 4.4 | 12 |
| 160 | Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 83-8   | 2.8 | 12 |

|     |   |     |    |
|-----|---|-----|----|
| 159 | Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients. <i>Anti-Cancer Drugs</i> , <b>2015</b> , 26, 872-7   | 2.4 | 12 |
| 158 | Pharmacogenetics in oncology: a promising field. <i>Current Pharmaceutical Design</i> , <b>2010</b> , 16, 155-63  | 3.3 | 12 |
| 157 | Perinatal dioxin exposure, cytochrome P-450 activity, liver functions and thyroid hormones at follow-up after 7-12 years. <i>Chemosphere</i> , <b>2008</b> , 70, 1865-72  | 8.4 | 12 |
| 156 | Genetic markers of treatment response in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , <b>2006</b> , 8, 369-77  | 4.9 | 12 |
| 155 | Risk assessment in clinical pharmacy. <i>International Journal of Clinical Pharmacy</i> , <b>2003</b> , 25, 98-103  |     | 12 |
| 154 | Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 567048                  | 5.6 | 12 |
| 153 | Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2017</b> , 6, 604-613                   | 4.5 | 11 |
| 152 | Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. <i>European Journal of Cancer</i> , <b>2017</b> , 86, 226-232 | 7.5 | 11 |
| 151 | Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer. <i>Clinical Pharmacokinetics</i> , <b>2018</b> , 57, 455-473  | 6.2 | 11 |
| 150 | Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2014</b> , 95, 383-5   | 6.1 | 11 |
| 149 | Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 73, 1303-6  | 3.5 | 11 |
| 148 | The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 501-7  | 3.2 | 11 |
| 147 | Pharmacogenetics of tomorrow: the 1 + 1 = 3 principle. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 1011-7   | 2.6 | 11 |
| 146 | Genetic factors are relevant and independent determinants of antihypertensive drug effects in a multiracial population. <i>American Journal of Hypertension</i> , <b>2009</b> , 22, 1295-302  | 2.3 | 11 |
| 145 | Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials. <i>European Journal of Clinical Pharmacology</i> , <b>2008</b> , 64, 1021-6   | 2.8 | 11 |
| 144 | Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio. <i>Fundamental and Clinical Pharmacology</i> , <b>2003</b> , 17, 355-62   | 3.1 | 11 |
| 143 | Pharmaceutical pictograms for low-literate patients: Understanding, risk of false confidence, and evidence-based design strategies. <i>Patient Education and Counseling</i> , <b>2017</b> , 100, 966-973  | 3.1 | 10 |
| 142 | Population pharmacokinetics of lenalidomide in multiple myeloma patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 79, 189-200   | 3.5 | 10 |



|     |   |      |    |
|-----|---|------|----|
| 141 | Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring. <i>European Journal of Endocrinology</i> , <b>2014</b> , 171, 677-83   | 6.5  | 10 |
| 140 | Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , <b>2014</b> , 759, 37-44           | 3.3  | 10 |
| 139 | The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients. <i>European Journal of Internal Medicine</i> , <b>2010</b> , 21, 293-6   | 3.9  | 10 |
| 138 | Pharmacogenetics in chemotherapy of colorectal cancer. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2009</b> , 23, 257-73   | 2.5  | 10 |
| 137 | Detailed analysis of IFN $\gamma$ response upon activation permits efficient isolation of cytomegalovirus-specific CD8 $^{+}$ T cells for adoptive immunotherapy. <i>Journal of Immunotherapy</i> , <b>2009</b> , 32, 513-23          | 5    | 10 |
| 136 | Individualization of cancer therapy based on cytochrome P450 polymorphism: a pharmacogenetic approach. <i>Cancer Treatment Reviews</i> , <b>1997</b> , 23, 321-39   | 14.4 | 10 |
| 135 | Use of plasmid-derived external quality control samples in pharmacogenetic testing. <i>Pharmacogenomics</i> , <b>2008</b> , 9, 1261-6   | 2.6  | 10 |
| 134 | Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients. <i>European Journal of Clinical Pharmacology</i> , <b>2007</b> , 63, 181-7  | 2.8  | 10 |
| 133 | Are Angiotensin II Receptor Antagonists Safe in Patients With Previous Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema?. <i>Hypertension</i> , <b>2001</b> , 37, E1  | 8.5  | 10 |
| 132 | Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <i>Pharmacogenetics and Genomics</i> , <b>2020</b> , 30, 131-144 | 1.9  | 10 |
| 131 | High-quality genotyping data from formalin-fixed, paraffin-embedded tissue on the drug metabolizing enzymes and transporters plus array. <i>Journal of Molecular Diagnostics</i> , <b>2015</b> , 17, 4-9                              | 5.1  | 9  |
| 130 | Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical Framework. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,  | 5.1  | 9  |
| 129 | A nationwide cross-sectional survey of pharmacy students on pharmacogenetic testing in The Netherlands. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 311-319   | 2.6  | 9  |
| 128 | The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 160-166                              | 3.5  | 9  |
| 127 | Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 82, 227-37                 | 3.8  | 9  |
| 126 | Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 73, 429-33  | 3.5  | 9  |
| 125 | CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 143, 171-9         | 4.4  | 9  |
| 124 | 5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study. <i>Fundamental and Clinical Pharmacology</i> , <b>2002</b> , 16, 39-47   | 3.1  | 9  |



|     |   |      |   |
|-----|---|------|---|
| 123 | Absence of cardiotoxicity of the experimental cytotoxic drug cyclopentenyl cytosine (CPEC) in rats. <i>Archives of Toxicology</i> , <b>2005</b> , 79, 268-76  | 5.8  | 9 |
| 122 | Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 617-627  | 6.1  | 9 |
| 121 | Toward predicting CYP2D6-mediated variable drug response from gene sequencing data. <i>Science Translational Medicine</i> , <b>2021</b> , 13,   | 17.5 | 9 |
| 120 | GenoChip CYP2D6 macroarray as a method to genotype for CYP2D6 variants: results of a validation study in a Caucasian population. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 681-7  | 2.6  | 8 |
| 119 | A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 1575-1586   | 3.8  | 8 |
| 118 | Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer. <i>PLoS ONE</i> , <b>2015</b> , 10, e0131091 | 3.7  | 8 |
| 117 | Phenotyping drug disposition in oncology. <i>Cancer Treatment Reviews</i> , <b>2012</b> , 38, 715-25  | 14.4 | 8 |
| 116 | Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study. <i>Drug Discovery Today</i> , <b>2009</b> , 14, 837-44   | 8.8  | 8 |
| 115 | Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients. <i>Annals of Oncology</i> , <b>2012</b> , 23, 3091-3097   | 10.3 | 8 |
| 114 | Multiplex pyrosequencing of two polymorphisms in DNA repair gene XRCC1. <i>Journal of Molecular Diagnostics</i> , <b>2006</b> , 8, 444-8  | 5.1  | 8 |
| 113 | A unifying model to predict variable drug response for personalised medicine  |      | 8 |
| 112 | Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 30, 167-173                        | 7.7  | 8 |
| 111 | Understanding clinical development of chimeric antigen receptor T cell therapies. <i>Cytotherapy</i> , <b>2017</b> , 19, 703-709  | 4.8  | 7 |
| 110 | Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 85-93  | 2.6  | 7 |
| 109 | Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2033-2044  | 3.8  | 7 |
| 108 | Technologies for Pharmacogenomics: A Review. <i>Genes</i> , <b>2020</b> , 11,   | 4.2  | 7 |
| 107 | Exposure-response analysis of endoxifen serum concentrations in early-breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 1141-1152  | 3.5  | 7 |
| 106 | A Genetic Polymorphism in Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2350-2356  | 12.9 | 7 |

|     |  |      |   |
|-----|--|------|---|
| 105 | Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 81, 179-182   | 3.5  | 7 |
| 104 | Pharmacogenetic biomarkers for predicting drug response. <i>Expert Review of Molecular Diagnostics</i> , <b>2014</b> , 14, 723-35  | 3.8  | 7 |
| 103 | Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment. <i>Pharmacogenetics and Genomics</i> , <b>2011</b> , 21, 461-8   | 1.9  | 7 |
| 102 | Alternative methods to a TaqMan assay to detect a tri-allelic single nucleotide polymorphism rs757210 in the HNF1B gene. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2011</b> , 50, 279-84  | 5.9  | 7 |
| 101 | Medication error due to ambiguous labelling of a commercial product. <i>International Journal of Clinical Pharmacy</i> , <b>2004</b> , 26, 10-1  |      | 7 |
| 100 | Pharmacokinetic-pharmacodynamic modeling of the inhibitory effect of erythromycin on tumour necrosis factor-alpha and interleukin-6 production. <i>Fundamental and Clinical Pharmacology</i> , <b>2001</b> , 15, 419-24  | 3.1  | 7 |
| 99  | Liver and kidney function in patients with Covid-19 treated with remdesivir. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 4450-4454   | 3.8  | 7 |
| 98  | Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review. <i>Pharmacogenomics Journal</i> , <b>2020</b> , 20, 159-168   | 3.5  | 7 |
| 97  | Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 591-604  | 6.1  | 7 |
| 96  | Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 529.e9-529.e16 | 2.8  | 6 |
| 95  | Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 49-55   | 3.5  | 6 |
| 94  | Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. <i>Pharmacological Research</i> , <b>2018</b> , 128, 122-129             | 10.2 | 6 |
| 93  | RAINFORST: a random forest approach to predict treatment benefit in data from (failed) clinical drug trials. <i>Bioinformatics</i> , <b>2020</b> , 36, i601-i609   | 7.2  | 6 |
| 92  | Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 2907-2925   | 3.8  | 6 |
| 91  | Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 693453  | 5.6  | 6 |
| 90  | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 76, 47-52   | 3.5  | 5 |
| 89  | An Electronic Health Record Text Mining Tool to Collect Real-World Drug Treatment Outcomes: A Validation Study in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 644-652  | 6.1  | 5 |
| 88  | The Dutch vision of clinical pharmacology. <i>Clinical Pharmacology and Therapeutics</i> , <b>2009</b> , 85, 366-8   | 6.1  | 5 |

|    |   |     |   |
|----|---|-----|---|
| 87 | Is rectal administration an alternative route for imatinib?. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2007</b> , 60, 623-4  | 3.5 | 5 |
| 86 | An accelerated stability study of 5-flucytosine in intravenous solution. <i>International Journal of Clinical Pharmacy</i> , <b>1999</b> , 21, 35-9   |     | 5 |
| 85 | Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. <i>Oncotarget</i> , <b>2017</b> , 8, 1204-1212  | 3.3 | 5 |
| 84 | Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 1                               | 6.2 | 5 |
| 83 | Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants. <i>Genes</i> , <b>2018</b> , 9,   | 4.2 | 5 |
| 82 | Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. <i>European Journal of Cancer</i> , <b>2018</b> , 104, 210-218  | 7.5 | 5 |
| 81 | Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. <i>Pharmacogenetics and Genomics</i> , <b>2017</b> , 27, 227-231  | 1.9 | 4 |
| 80 | Adverse drug reactions on sexual functioning: a systematic overview. <i>Drug Discovery Today</i> , <b>2019</b> , 24, 890-897  | 8.8 | 4 |
| 79 | The impact of estimated tumour purity on gene expression-based drug repositioning of Clear Cell Renal Cell Carcinoma samples. <i>Scientific Reports</i> , <b>2019</b> , 9, 2495   | 4.9 | 4 |
| 78 | Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 1267-76 | 2.6 | 4 |
| 77 | Breath tests to phenotype drug disposition in oncology. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 919-26   | 6.2 | 4 |
| 76 | Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 945-953   | 2.6 | 4 |
| 75 | A novel specific pyrosequencing method for genotyping FCGR3A rs396991 without coamplification of homologous gene FCGR3B. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 631-5   | 1.9 | 4 |
| 74 | Cost-Benefit Analysis of Vaccination Against Influenza of Employees from an Academic Medical Centre. <i>Disease Management and Health Outcomes</i> , <b>2002</b> , 10, 579-587  |     | 4 |
| 73 | Prospective study evaluating the effect of impaired tamoxifen metabolism on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 523-523        | 2.2 | 4 |
| 72 | Transcriptome Signature Reversion as a Method to Reposition Drugs Against Cancer for Precision Oncology. <i>Cancer Journal (Sudbury, Mass )</i> , <b>2019</b> , 25, 116-120   | 2.2 | 4 |
| 71 | Treatment Algorithm for Homozygous or Compound Heterozygous Variant Allele Carriers With Low-Dose Capecitabine.. <i>JCO Precision Oncology</i> , <b>2017</b> , 1, 1-10  | 3.6 | 3 |
| 70 | Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients. <i>Pharmacogenetics and Genomics</i> , <b>2015</b> , 25, 279-88  | 1.9 | 3 |

|    |  |     |   |
|----|--|-----|---|
| 69 | Pharmacogenetics of taste: turning bitter pills sweet?. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 111-9  | 2.6 | 3 |
| 68 | Differences in 5-hydroxytryptamine-3B haplotype frequencies between Asians and Caucasians. <i>International Journal of Biological Markers</i> , <b>2012</b> , 27, 34-8   | 2.8 | 3 |
| 67 | Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia. <i>Leukemia Research</i> , <b>2007</b> , 31, 1545-51   | 2.7 | 3 |
| 66 | Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, CRA509-CRA509  | 2.2 | 3 |
| 65 | Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. <i>European Journal of Human Genetics</i> , <b>2021</b> ,  | 5.3 | 3 |
| 64 | Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants in and and Methotrexate Levels and Toxicities. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 1241   | 5.6 | 3 |
| 63 | Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3574-3574   | 2.2 | 3 |
| 62 | Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 1925-1931 | 3.6 | 3 |
| 61 | Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 191-203  | 6.2 | 3 |
| 60 | Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. <i>PLoS ONE</i> , <b>2018</b> , 13, e0208080   | 3.7 | 3 |
| 59 | Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse. <i>Scientific Reports</i> , <b>2021</b> , 11, 415   | 4.9 | 3 |
| 58 | Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. <i>Pharmacogenomics Journal</i> , <b>2019</b> , 19, 473-479   | 3.5 | 2 |
| 57 | Reply to C.L. Braal et al, H. Brauch et al, and M.P. Goetz et al. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1984-1985  | 2.8 | 2 |
| 56 | SLC04A1, SLC22A2 and SLC28A2 variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 613-619   | 2.6 | 2 |
| 55 | Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule. <i>Internal and Emergency Medicine</i> , <b>2014</b> , 9, 481-2                                      | 3.7 | 2 |
| 54 | Pharmacogenetics in transplant patients: mind the mix. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 94, 443-4   | 6.1 | 2 |
| 53 | Outcomes of an antimicrobial control program in a Dutch hospital. <i>American Journal of Health-System Pharmacy</i> , <b>2004</b> , 61, 1702-6   | 2.2 | 2 |
| 52 | A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 523-523                    | 2.2 | 2 |

|    |   |      |   |
|----|---|------|---|
| 51 | UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.. <i>European Journal of Cancer</i> , <b>2022</b> , 162, 148-157   | 7.5  | 2 |
| 50 | A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices. <i>Biomedical Chromatography</i> , <b>2020</b> , 34, e4732   | 1.7  | 2 |
| 49 | An estimation of patients at potential risk for drug-induced sexual dysfunction using pharmacy dispensing data. <i>Family Practice</i> , <b>2021</b> , 38, 292-298  | 1.9  | 2 |
| 48 | Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 1201-1215  | 6.2  | 2 |
| 47 | 3D printed furosemide and sildenafil tablets: Innovative production and quality control. <i>International Journal of Pharmaceutics</i> , <b>2021</b> , 603, 120694  | 6.5  | 2 |
| 46 | Confirmation practice in pharmacogenetic testing; how good is good enough?. <i>Clinica Chimica Acta</i> , <b>2019</b> , 490, 77-80  | 6.2  | 2 |
| 45 | Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 89-102   | 6.2  | 2 |
| 44 | The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome. <i>European Journal of Pharmaceutical Sciences</i> , <b>2018</b> , 114, 24-29                            | 5.1  | 2 |
| 43 | Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 28, 99.e1-99.e1 |      | 2 |
| 42 | Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance.. <i>Scientific Reports</i> , <b>2022</b> , 12, 4206  | 4.9  | 2 |
| 41 | DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - AuthorsMeply. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e67   | 21.7 | 1 |
| 40 | Pharmacogenetics in electroconvulsive therapy and adjunctive medications. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 1015-31   | 2.6  | 1 |
| 39 | Formulation, quality control and shelf life of the experimental cytostatic drug cyclopentenyl cytosine. <i>Drug Development and Industrial Pharmacy</i> , <b>2006</b> , 32, 497-503   | 3.6  | 1 |
| 38 | A splinter. <i>International Journal of Clinical Pharmacy</i> , <b>2001</b> , 23, 123   |      | 1 |
| 37 | Contribution of Common and Rare Genetic Variants in CEP72 on Vincristine-Induced Peripheral Neuropathy in Brain Tumor Patients.. <i>British Journal of Clinical Pharmacology</i> , <b>2022</b> ,  | 3.8  | 1 |
| 36 | CYP3A4 phenotyping with midazolam to predict sunitinib exposure.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2592-2592   | 2.2  | 1 |
| 35 | Genetic variation in CYP19A1 and occurrence of adverse events in exemestane treatment with early breast cancer patients in the Dutch TEAM trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e22152-e22152   | 2.3  | 1 |
| 34 | Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle. <i>Pharmacogenomics Journal</i> , <b>2021</b> ,   | 3.5  | 1 |

|    |   |     |   |
|----|---|-----|---|
| 33 | Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 577968 | 5.6 | 1 |
| 32 | Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics. <i>Mycoses</i> , <b>2021</b> , 64, 1111-1116   | 5.2 | 1 |
| 31 | Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation. <i>Drug Discovery Today</i> , <b>2021</b> , 26, 2527-2546   | 8.8 | 1 |
| 30 | Non-Cancer Drug Repurposing Candidates for Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2019</b> , 25, 147-148  | 2.2 | 1 |
| 29 | Substrate specificity of CYP2D6 genetic variants. <i>Pharmacogenomics</i> , <b>2021</b> , 22, 1081-1089   | 2.6 | 1 |
| 28 | Quantitative analysis of the experimental cytotoxic drug cyclopentenyl cytosine and its metabolite in plasma with HPLC tandem mass spectrometry. <i>Biomedical Chromatography</i> , <b>2008</b> , 22, 1368-73   | 1.7 | 0 |
| 27 | Learning From Consultations Conducted by Community Pharmacists in Northern Ireland for Nonprescription Sildenafil: A Qualitative Study Using the Theoretical Domains Framework. <i>Sexual Medicine</i> , <b>2021</b> , 9, 100440                                    | 2.7 | 0 |
| 26 | One non-believer: Response to "Obviously Nine Believers: Actionable Germline Genetic Variants for Pre-emptive Pharmacogenetic Testing". <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2019</b> , 126, 7  | 3.1 | 0 |
| 25 | Detecting DPD deficiency: when perfect is the enemy of good. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 87, 717-719  | 3.5 | 0 |
| 24 | Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where do We Stand?. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 826004   | 5.6 | 0 |
| 23 | Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 803935  | 5.6 | 0 |
| 22 | Pharmacogenetics: optimising prescribing in primary care. <i>The Prescriber</i> , <b>2022</b> , 33, 10-13   | 0.4 | 0 |
| 21 | Genome-Wide Analyses of Nephrotoxicity in Platinum-Treated Cancer Patients Identify Association with Genetic Variant in RBMS3 and Acute Kidney Injury. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 892  | 3.6 | 0 |
| 20 | Unlicensed pharmaceutical preparations for clinical patient care: Ensuring safety. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 3-8  | 2.6 |   |
| 19 | Reply to R. Ferraldeschi et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e586-e586   | 2.2 |   |
| 18 | Pharmacogenetics in the future treatment of rheumatology. <i>Future Rheumatology</i> , <b>2007</b> , 2, 337-339   |     |   |
| 17 | Toxicity and Effectivity of the Experimental Cytotoxic Drug Cyclopentenyl Cytosine in NOD/scid Mice with Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , <b>2005</b> , 106, 4574-4574   | 2.2 |   |
| 16 | Generation of GMP-Grade CMV pp65-Specific CD8+ and CD4+ Donor T Cell Lines for Treatment of CMV Reactivation after Transplantation.. <i>Blood</i> , <b>2006</b> , 108, 2931-2931  | 2.2 |   |



|    |  |     |
|----|--|-----|
| 15 | Variation in the ESR-1 gene as a prognostic marker in early breast cancer survival.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 11074-11074   | 2.2 |
| 14 | Treosulfan-Based Conditioning in Pediatric Hematopoietic Stem Cell Transplantation: A Prospective Study on Pharmacokinetics and Early Clinical Outcomes. <i>Blood</i> , <b>2014</b> , 124, 3865-3865                                       | 2.2 |
| 13 | CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4548-4548  | 2.2 |
| 12 | Sequence Dependent Efficiency of Cross-Presentation in MHC Class I Requires Rational Design of Long Synthetic Peptides for Vaccination or Ex Vivo Activation. <i>Blood</i> , <b>2008</b> , 112, 3904-3904                                  | 2.2 |
| 11 | Genetic variation in CYP19A1 and response to exemestane: Survival in early breast cancer in the Dutch TEAM trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10518-10518   | 2.2 |
| 10 | Pharmacokinetics (PK) of panitumumab in a single patient with metastatic colorectal cancer (mCRC) and liver dysfunction.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 594-594  | 2.2 |
| 9  | The influence of gastrointestinal resection on sunitinib exposure in GIST patients.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 10547-10547   | 2.2 |
| 8  | Safety and efficacy of the addition of simvastatin to panitumumab in KRAS mutant metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e14558-e14558   | 2.2 |
| 7  | Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 595-595   | 2.2 |
| 6  | CYP2D6 genotype related to tamoxifen efficacy: An analysis with exclusion of potential false CYP2D6 genotype assignment caused by loss of heterozygosity in tumor tissue.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 597-597 | 2.2 |
| 5  | Safety and efficacy of the addition of simvastatin to cetuximab in KRAS mutant metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e14586-e14586   | 2.2 |
| 4  | Precision Medicine Using Pharmacogenomic Panel-Testing. <i>Advances in Molecular Pathology</i> , <b>2020</b> , 3, 131-142  | 0.3 |
| 3  | Response: Limited sampling strategies for once daily tacrolimus exposure monitoring. <i>European Journal of Clinical Pharmacology</i> , <b>2016</b> , 72, 775-6  | 2.8 |
| 2  | Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool. <i>Scientific Reports</i> , <b>2021</b> , 11, 19084  | 4.9 |
| 1  | Respiratory Adherence Care Enhancer Questionnaire: Identifying Self-Management Barriers of Inhalation Corticosteroids in Asthma.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 767092  | 5.6 |